The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Daratumumab and dexamethasone in the treatment of patients with myeloma and severe renal impairment
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses a prospective Phase II study which aimed to evaluate the safety and efficacy of daratumumab plus dexamethasone in patients with relapsed/refractory (R/R) myeloma with severe renal impairment or those undergoing dialysis. Dr Kastritis shares some results on the overall response rate and progression-free survival (PFS) observed in patients and the importance of these findings for this patient population. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
